FDA Cancels Proposed Rule On Clinical Trial Malfeasance
Executive Summary
US FDA has withdrawn a proposed rule that would have required sponsors to notify FDA if they became aware of data falsification during a clinical trial. Industry had been critical of the 2010 proposal.